BR112021007006A2 - derivados de (piridin-2-il)amina como inibidores de tgf-beta r1(alk5) para o tratamento de câncer - Google Patents

derivados de (piridin-2-il)amina como inibidores de tgf-beta r1(alk5) para o tratamento de câncer Download PDF

Info

Publication number
BR112021007006A2
BR112021007006A2 BR112021007006-0A BR112021007006A BR112021007006A2 BR 112021007006 A2 BR112021007006 A2 BR 112021007006A2 BR 112021007006 A BR112021007006 A BR 112021007006A BR 112021007006 A2 BR112021007006 A2 BR 112021007006A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
ring
compound
acceptable salt
alkyl
Prior art date
Application number
BR112021007006-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Tom Yao-Hsiang Wu
Qihui Jin
Original Assignee
Nexys Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexys Therapeutics, Inc. filed Critical Nexys Therapeutics, Inc.
Publication of BR112021007006A2 publication Critical patent/BR112021007006A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021007006-0A 2018-12-27 2019-12-17 derivados de (piridin-2-il)amina como inibidores de tgf-beta r1(alk5) para o tratamento de câncer BR112021007006A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785616P 2018-12-27 2018-12-27
US62/785,616 2018-12-27
PCT/US2019/066993 WO2020139636A1 (en) 2018-12-27 2019-12-17 (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112021007006A2 true BR112021007006A2 (pt) 2021-08-10

Family

ID=69185691

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007006-0A BR112021007006A2 (pt) 2018-12-27 2019-12-17 derivados de (piridin-2-il)amina como inibidores de tgf-beta r1(alk5) para o tratamento de câncer

Country Status (16)

Country Link
US (2) US12102626B2 (https=)
EP (1) EP3902796B1 (https=)
JP (2) JP7515049B2 (https=)
KR (1) KR102832376B1 (https=)
CN (1) CN113348167B (https=)
AR (1) AR117539A1 (https=)
AU (1) AU2019417418B2 (https=)
BR (1) BR112021007006A2 (https=)
CA (1) CA3117838A1 (https=)
EA (1) EA202191619A1 (https=)
ES (1) ES2972516T3 (https=)
IL (1) IL284266B2 (https=)
MX (1) MX2021007738A (https=)
SG (1) SG11202103457PA (https=)
TW (1) TWI884934B (https=)
WO (1) WO2020139636A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021259419A1 (en) 2020-04-21 2022-11-10 Lexicon Pharmaceuticals, Inc. AAK1 inhibitors for use in treating viral infections
AU2021258128A1 (en) 2020-04-21 2022-11-03 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-5-yl)piperazine for use in the the treatment of COV-229E or COV-OC43 coronaviruses infections
CN113214111A (zh) * 2021-04-30 2021-08-06 上海立科化学科技有限公司 3-(2-氰基苯基)丙酸及4-氰基-1-茚满酮的制备方法
US12263576B2 (en) 2021-08-19 2025-04-01 Hyundai Mobis Co., Ltd. Robot system for automated assembly of modular component
EP4464694A4 (en) * 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
CN121554469B (zh) * 2026-01-23 2026-04-17 四川大学华西医院 一种alk5 protac化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287857B6 (sk) 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
JP5934782B2 (ja) * 2011-05-04 2016-06-15 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. アミノ−ピリジン含有脾臓チロシンキナーゼ(Syk)阻害薬
WO2014048065A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2934525B1 (en) * 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
CN106536507B (zh) 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
TWI582083B (zh) 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018520201A (ja) 2015-07-23 2018-07-26 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tgfベーター受容体アンタゴニスト
WO2020103817A1 (zh) 2018-11-20 2020-05-28 南京圣和药业股份有限公司 TGF-βR1抑制剂及其应用
JP7499284B2 (ja) 2019-06-25 2024-06-13 インベンティスバイオ カンパニー リミテッド 複素環化合物、その製造方法及びその使用方法
CN112707902B (zh) 2020-03-23 2022-04-15 杭州阿诺生物医药科技有限公司 TGF-β受体抑制剂

Also Published As

Publication number Publication date
KR20210110316A (ko) 2021-09-07
CN113348167B (zh) 2026-01-09
JP2022517730A (ja) 2022-03-10
US20220054465A1 (en) 2022-02-24
EP3902796C0 (en) 2024-02-07
EP3902796B1 (en) 2024-02-07
SG11202103457PA (en) 2021-05-28
TWI884934B (zh) 2025-06-01
AU2019417418A1 (en) 2021-04-15
EP3902796A1 (en) 2021-11-03
EA202191619A1 (ru) 2021-09-28
IL284266B2 (en) 2024-06-01
CN113348167A (zh) 2021-09-03
KR102832376B1 (ko) 2025-07-09
CA3117838A1 (en) 2020-07-02
US12102626B2 (en) 2024-10-01
ES2972516T3 (es) 2024-06-13
TW202039436A (zh) 2020-11-01
AU2019417418B2 (en) 2025-02-27
AR117539A1 (es) 2021-08-11
IL284266B1 (en) 2024-02-01
MX2021007738A (es) 2021-08-05
JP2023052437A (ja) 2023-04-11
IL284266A (en) 2021-08-31
NZ775362A (en) 2025-02-28
JP7515049B2 (ja) 2024-07-12
US20240398776A1 (en) 2024-12-05
WO2020139636A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
BR112021007006A2 (pt) derivados de (piridin-2-il)amina como inibidores de tgf-beta r1(alk5) para o tratamento de câncer
CN107922431B (zh) Hpk1抑制剂及其使用方法
EA027120B1 (ru) Противофиброзные пиридиноны
CN109810041A (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
JP2022532719A (ja) Acss2阻害剤およびその使用方法
JP7776068B2 (ja) 癌、網膜障害及び心筋症の治療のための三置換ピリミジン化合物及び組成物
JP7824282B2 (ja) 縮合ヘテロアリール化合物およびCaMKII阻害剤としてのその使用
KR20170129874A (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
KR20240005892A (ko) Lpa 수용체 길항제 및 이의 용도
JP7282743B2 (ja) 複素環化合物
JP7025359B2 (ja) ネクローシス阻害剤であるヘテロアリール化合物、その組成物及び用途
EA043088B1 (ru) Производные (пиридин-2-ил)амина в качестве ингибиторов tgf-бета r1 (alk5) для лечения злокачественных новообразований
HK40063493A (en) (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
HK40063493B (en) (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
JP2025521719A (ja) c-MYC mRNA翻訳調節因子及び癌治療におけるその使用
BR112019021790A2 (pt) compostos bicíclicos e métodos de uso

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022025720-8 PROTOCOLO 870220118165 EM 15/12/2022 17:52.

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]